I'M OVER 50

I HAVE SEVERAL UNDERLYING COMORBIDITIES

I'M SUSPECTED TO HAVE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP)

I DESERVE A
CLOSER LOOK

XENLETA: For the patients most at risk, efficacy against typical and atypical CABP pathogens in as little as 5 days of oral treatment.1,2

Appropriate treatment for patients most at risk of negative outcomes with CABP

Explore our patient profiles to see case studies illustrating when to consider XENLETA and how it may help patients like yours.


See the profiles

Demonstrated monotherapy efficacy

XENLETA achieved early and effective clinical response against common CABP pathogens, including gram-positive, gram-negative, and atypical pathogens, in as short as 5 total days of therapy.1


See the results

Low risk of resistance and cross-resistance due to novel MOA

XENLETA is the first and only oral pleuromutilin antibiotic that may remain active against clinical isolates resistant to other treatments.1


Get the details

Discuss XENLETA in person

Request a visit from a sales representative to learn more about XENLETA. Your sales rep can also provide sample packs.

Request a rep/sample pack